Imagine a future where cutting-edge cancer treatments are developed and tested right on a university campus, offering new hope to patients. That future is now a reality at the University of Missouri (Mizzou), where a groundbreaking clinical trial has just begun, marking a significant milestone in the fight against liver cancer.
In a bold move, Mizzou's School of Medicine and MU Health Care have teamed up with ABK Biomedical to launch their first-ever on-campus radiopharmaceutical clinical trial. But here's where it gets even more exciting: the therapy being tested, Eye90 microspheres®, is manufactured at the university's own research reactor, showcasing the incredible research capabilities that Mizzou has to offer. This trial is a testament to the university's ability to take a treatment from the development stage, through rigorous testing, and into human clinical trials – all under one roof.
And this is the part most people miss: Mizzou's research reactor is the largest of its kind in the nation, and its facilities for veterinary medicine, medicine, and precision health are unparalleled. This unique combination allows researchers to collaborate with industry leaders, accelerating the development and testing of innovative treatments, and ultimately getting them to patients faster. As Mizzou President Mun Choi puts it, 'This clinical trial demonstrates the power of our campus research, enabling us to partner with industry and bring groundbreaking treatments to patients from a single location.'
So, what makes Eye90 microspheres so special? These tiny radiopaque glass beads are embedded with yttrium-90 (Y-90), a radioisotope that targets unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer. Here's the controversial part: while some may argue that traditional radiation therapy is sufficient, Eye90's unique design allows for precise visualization during delivery, enabling interventional radiologists and oncologists to accurately target tumors with localized radiation therapy. This approach aims to improve treatment efficacy while minimizing damage to surrounding healthy tissue – a game-changer for patients with limited treatment options.
As Ryan Davis, associate professor of clinical radiology at Mizzou's School of Medicine, explains, 'This trial provides early access to a promising therapy for our patients and reinforces our leadership in translational research. We're thrilled to be part of this study, as we recognize the growing importance of targeted radiotherapy for metastatic tumors.'
But wait, there's more: Mizzou has been at the forefront of Y-90 therapy since the 1980s, when researchers Delbert Day and Gary Ehrhardt collaborated to create the first microsphere treatment, TheraSphere. This treatment received full FDA approval in 2021, and Mizzou remains the sole US producer. Now, with the Eye90 microspheres, Mizzou is pushing the boundaries of nuclear medicine even further. Matt Sanford, executive director of the Mizzou Research Reactor, notes that 'Our partnerships with companies like ABK Biomedical are advancing cancer care not only in Columbia but also across the country and around the world.'
The clinical trial, led by Mizzou researchers, builds upon extensive preclinical studies conducted in small animal models and dogs with hepatocellular carcinoma. These studies, funded by ABK Biomedical, demonstrated the safety and effectiveness of Eye90 microspheres, paving the way for human clinical trials. The trial involves a single administration of the microspheres, followed by a year-long monitoring period to assess patient outcomes, including tumor response and quality of life.
As we look to the future, it's clear that this innovative therapy has the potential to revolutionize the treatment of unresectable liver tumors. But what do you think? Is targeted radiotherapy the future of cancer treatment, or are there potential risks and limitations that need to be addressed? And as Mizzou continues to pioneer advanced treatments, what other breakthroughs can we expect from this powerhouse of research and collaboration? We'd love to hear your thoughts in the comments below.
